Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma

[1]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Anderson,et al.  Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. , 2015, Blood.

[3]  C. Printz.  NCI launches exceptional responders initiative: Researchers will attempt to identify why some patients respond to treatment so much better than others , 2015, Cancer.

[4]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[5]  M. Dimopoulos,et al.  Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma , 2014, Blood Cancer Journal.

[6]  Christian Jacques,et al.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. , 2014, The New England journal of medicine.

[7]  C. Sheridan.  Cancer centers zero in on exceptional responders , 2014, Nature Biotechnology.

[8]  D. Dingli,et al.  Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma , 2013 .

[9]  T. Therneau,et al.  Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma , 2013, Leukemia.

[10]  N. Nassif,et al.  Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance , 2013, Blood Cancer Journal.

[11]  R. Fonseca,et al.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma , 2013, Leukemia.

[12]  P. L. Bergsagel,et al.  Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. , 2013, Blood.

[13]  Lust,et al.  Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. , 2012, Blood.

[14]  A. Hagenbeek,et al.  Multiple myeloma and the road to personalised medicine. , 2011, The Lancet. Oncology.

[15]  P. Sonneveld,et al.  Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.

[16]  D. Esseltine,et al.  Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. , 2010, Blood.

[17]  A. Chanan-Khan,et al.  Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Robert A Kyle,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.

[19]  H. Avet-Loiseau,et al.  The role of complete response in multiple myeloma. , 2009, Blood.

[20]  G. Ahmann,et al.  Genomic abnormalities in monoclonal gammopathy of undetermined significance. , 2002, Blood.

[21]  D. Harrington,et al.  Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. , 2002, Cancer research.

[22]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[23]  A. Poh,et al.  In search of exceptional responders. , 2015, Cancer discovery.

[24]  P. L. Bergsagel,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. , 2013, Mayo Clinic proceedings.

[25]  R. Fonseca,et al.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.

[26]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.